Historically, dietitians played a minor part in the management of inflammatory bowel disease
(IBD), including Crohn's disease and ulcerative colitis. Patients were commonly referred for …

Environmental and lifestyle factors play an important role in the natural history of Crohn's
disease and ulcerative colitis. A group of international experts from the International …

Objective The aim of this systematic review and meta-analysis of longitudinal studies was to
ascertain to effects of TNF-α inhibitor therapy on body weight and BMI. Methods Three …

Obesity is prevalent within the inflammatory bowel disease (IBD) population, particularly in
newly developed countries. Several epidemiological studies have suggested that 15%-40 …

In contrast to previous perceptions that inflammatory bowel disease (IBD) patients are
generally malnourished and underweight, there is mounting evidence to suggest that rates …

The number of available biological therapies have doubled over the last 10 years and the
arrival of novel molecules (interleukin 23p19 inhibitors) is ongoing alongside the …

Background Infliximab is a chimeric monoclonal antibody against tumour necrosis factor‐
alpha for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Recently, a …

METHODS: We created an EHR-based cohort of adult patients with IBD who were new
users of biologic agents (tumor necrosis factor [TNF-α] antagonists, ustekinumab, and …

Introduction Studies in patients with immune-mediated inflammatory diseases (IMIDs) have
inconsistently suggested that anti-TNFα therapy may be associated with excessive weight …

Background Data describing the effect of obesity on antitumor necrosis factor (anti-TNF)
treatment response are inconsistent. Visceral adipose tissue (VAT) is a superior marker of …